A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy

Journal of Cellular Biochemistry

Volumn 104, Issue 1, 2008, Pages 189-201

  Wȩsierska Ga̧dek, Józefa ^a   Kramer, Matthias P ^a   Schmid, Gerald ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

Author keywords

Apoptosis; c Ha ras; Cisplatin; Farnesyl protein transferase; HeLa cells

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; CISPLATIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; METHIONINE; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; PROTEIN P21; TRANSFERASE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL FRACTIONATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; PRIORITY JOURNAL; THERAPY EFFECT; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; PATHOLOGY; UTERINE CERVIX TUMOR;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CISPLATIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HELA CELLS; HUMANS; METHIONINE; PROTO-ONCOGENE PROTEINS P21(RAS); UTERINE CERVICAL NEOPLASMS;

EID: 46449126051     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21612     Document Type: Article

References (36)

1. Appels NM, Beijnen JH, Schellens JH. 2005. Development of farnesyl transferase inhibitors: A review. Oncologist 10:565-578.
2. Bishop WR, Kirschmeier P, Baum C. 2003. Farnesyl transferase inhibitors: Mechanism of action, translational studies and clinical evaluation. Cancer Biol Ther 2:S96-S104.
3. Caponigro F, Casale M, Bryce J. 2003. Farnesyl transferase inhibitors in clinical development. Exp Opin Investig Drugs 12:943-954.
4. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ. 2001. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289-2293.
5. Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C. 2002. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100:43-48.
6. Doll RJ, Kirschmeier P, Bishop WR. 2004. Farnesyltransferase inhibitors as anticancer agents: Critical crossroads. Curr Opin Drug Discov Dev 7:478-486.
7. Fokstuen T, Rabo YB, Zhou JN, Karlson J, Platz A, Shoshan MC, Hansson J, Linder S. 1997. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anticancer Res 17:2347-2352.
8. Horky M, Wurzer G, Kotala V, Anton M, Vojtesek B, Vacha J, Wesierska-Gadek J. 2001. Segregation of nucleolar components coincides with caspase-3 activation in cisplatin-treated HeLa cells. J Cell Sci 114:663-670.
9. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. 2002. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. J Cell Biol 156:299-313.
10. Khwaja A, Dockrell ME, Hendry BM, Sharpe CC. 2006. Prenylation is not necessary for endogenous Ras activation in non-malignant cells. J Cell Biochem 97:412-422.
11. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. 2003. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 89:2133-2139.
12. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. 2002. Chemoradiation of cervical cancer cells: Targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62:7364-7371.
13. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. 1995. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806.
14. Liang XJ, Mukherjee S, Shen DW,Maxfield FR, Gottesman MM. 2006. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 66:2346-2353.
15. Margaritora S, Cesario A, Porziella V, Granone P, Catassi A, Russo P. 2005. Farnesyltransferase inhibitors: Overview of their action and role in solid malignancy therapy. Lett Drug Des Discov 2:26-35.
16. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. 1998. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95:1369-1374.
17. Schloffer D, Horky M, Kotala V, Wesierska-Gadek J. 2003. Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin. Cancer Detect Prev 27:481-493.
18. Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, Der CJ, Coffey RJ. 1999. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology 117:567-576.
19. Smalley KS, Eisen TG. 2003. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165-175.
20. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J. 2006. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58:776-784.
21. Vindelov LL, Christensen IJ, Nissen NI. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327.
22. Wesierska-Gadek J. 2005. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action. J Cell Biochem 95:1012-1028.
23. Wesierska-Gadek J, Schmid G. 2000. Overexpressed poly (ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80:85-103.
24. Wesierska-Gadek J, Schmid G. 2001. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell Mol Biol Lett 6:117-140.
25. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. 1995. Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Acta Biochim Pol 42:197-200.
26. Wesierska-Gadek J, Bugajska-Schretter A, Cerni C. 1996a. ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified. J Cell Biochem 62:90-101.
27. Wesierska-Gadek J, Schmid G, Cerni C. 1996b. ADP-ribosylation of wild-type p53 in vitro: Binding of p53 protein to specific p53 consensus sequence prevents its modification. Biochem Biophys Res Commun 224:96-102.
28. Wesierska-Gadek J, Wang ZQ, Schmid G. 1999. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 59:28-34.
29. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101:128-136.
30. Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A. 2004. Increased susceptibility of poly(-ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64:4487-4497.
31. Wesierska-Gadek J, Gueorguieva M, Horky M. 2005a. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4:113-124.
32. Wesierska-Gadek J, Gueorguieva M, Ranftler C, Zerza-Schnitzhofer G. 2005b. A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death. J Cell Biochem 96:1-7.
33. Wesierska-Gadek J, Kramer M, Schmid G. 2006. Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells. J Cell Biochem 99:1664-1676.
34. Wesierska-Gadek J, Maurer M, Schmid G. 2007. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest. J Cell Biochem 102:736-747.
35. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106:486-495.
36. Yim EK, Lee KH, Kim CJ, Park JS. 2006. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int J Gynecol Cancer 16:690-697.